Gufic Biosciences logo

Gufic Biosciences financials: balance sheet, profit and loss, cash flow

NSE: GUFICBIOBSE: 509079Pharmaceuticals & BiotechnologySmall Cap

Gufic Biosciences Limited · Face value ₹1 · Listed Aug 1985 on BSE, Oct 2004 on NSE
Last close ₹418.80down ₹4.95 (1.17%)BSE ₹420.40

Share price at the NSE close on 29 Oct 2026. Previous close ₹423.75.

29 Oct: open ₹423.00, high ₹424.05, low ₹416.25

52-week range of traded prices to 29 Oct 2026
₹268.00Low, 9 Mar 2026₹467.80High, 7 Sep 2026
Market cap
₹4,200 Cr959th largest listed
P/E
57.17
P/B
6.32
Dividend yield
0.02%
ROE
11.6%
ROCE
12.7%
Debt to equity
0.58
Volume, NSE
26,73756.8% delivered

Gufic Biosciences' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Gufic Biosciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
24911Mar 1730416Mar 183502296Mar 1935823107Mar 204884452Mar 217799654Mar 2269180311Mar 2380786317Mar 2482070310Mar 2594063385Mar 26

Operating and net margin, per cent

  • Operating margin
  • Net margin
19.5%4.6%10.9%12.5%13.0%12.5%17.2%18.7%19.5%18.1%16.5%16.0%4.6%5.3%6.2%6.4%9.1%12.3%11.5%10.7%8.5%6.7%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 4.1% of operating profit in the first full year.

The years either side of a change of basis do not compare. From the year to Mar 2021, the company's revenue for that year, ₹488 Cr, differs from its quarters added, ₹451 Cr.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue940
  2. Materials and goods−421
  3. Employee costs−152
  4. Other expenses−217
  5. Operating profit150
  6. Depreciation−31
  7. Other income+2.6
  8. One-off items0.0
  9. Finance costs−37
  10. Profit before tax85
  11. Tax−22
  12. Net profit63

What the company owns

  • Plant, investments and other assets₹645 Cr
  • Inventory₹324 Cr
  • Receivables₹297 Cr
  • Cash and bank₹74 Cr

What pays for it: net worth and liabilities

  • Net worth₹664 Cr
  • Borrowings₹385 Cr
  • Owed to suppliers₹199 Cr
  • Other liabilities₹93 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Gufic Biosciences quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026Twelve monthsFiled 14 Aug
Revenue from operations249304350358488779691807820940974
222266305313404633556661685790810
Materials and goods bought121145181177250412332390375421431
Employee costs41–4752668687110127152157
Other expenses60–778487136137161183217221
Operating profit before depreciation2738464584146135146135150165
Operating margin10.9%12.5%13.0%12.5%17.2%18.7%19.5%18.1%16.5%16.0%16.9%
Materials, % of revenue48.5%–51.6%49.6%51.3%52.9%48.0%48.3%45.7%44.8%44.2%
Employee costs, % of revenue16.5%–13.4%14.4%13.6%11.0%12.6%13.6%15.5%16.1%16.2%
Other expenses, % of revenue24.2%–22.0%23.5%17.9%17.4%19.9%20.0%22.3%23.1%22.7%
Depreciation and amortisation445816172217213131
Operating profit after depreciation2334413668129112129114120134
Other income13574332432
Finance costs691013145815233737
Profit before one-off items and tax1828353058127107116948599
One-off items–2000000000
Profit before tax1830353058127107116948599
71414713312730242226
Net profit1116222344968086706374
Other comprehensive income––0−20000000
Total comprehensive income––222145958086706474
Net margin4.6%5.3%6.2%6.4%9.1%12.3%11.5%10.7%8.5%6.7%7.5%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2018 they do not, so they are left blank.
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations5452637284100123152202
504758667789111137183
Materials and goods bought1916–4045516681102
Employee costs––––55121932
Other expenses––––2733333749
Operating profit before depreciation4556711121420
Operating margin8.1%9.2%8.4%8.7%8.4%11.1%9.9%9.5%9.8%
Materials, % of revenue––––53.6%50.8%53.7%53.5%50.4%
Employee costs, % of revenue––––5.5%5.4%9.7%12.7%15.8%
Other expenses, % of revenue––––32.4%32.7%26.7%24.2%24.0%
Depreciation and amortisation222222244
Operating profit after depreciation334459101116
Other income100000001
Finance costs232234445
Profit before one-off items and tax–122356711
One-off items–1–––––––
Profit before tax2222356711
110112234
Net profit111123447
Net margin2.3%1.6%1.9%2.0%1.8%3.3%3.5%2.5%3.6%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7596173269348533601664
Share capital88101010101010
Reserves6888164259338523591654
961075254311317310385
181225164187288372388518
18365565225188181160
Total assets2743563925218611,0931,1701,342
4493131201397492546541
230263261321464600624800
Net debt88973927265304282311
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
82104−27−712344
9813812014656
11−9−135−1308−94
Receivables−19−23−55−1537−24
Inventories28−21−68−17−16−108
Payables134−12401736
Other working capital110111
Tax paid−9−33−28−27−23−12
Interest paid−1200000
Capital spending14891881137631
Free cash flow6816−214−1204713
−14−96−191−102−72−31
−66−323482−3732
Dividends paid011111
Shares bought back000000
Shares issued00010000
Net change in cash2517−271445
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Gufic Biosciences dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Earnings per share₹1.48₹2.07₹2.80₹2.94₹4.56₹9.89₹8.22₹8.74₹6.97₹6.30
Diluted earnings per share₹1.48₹2.07₹2.80₹2.94₹4.56₹9.89₹8.22₹8.74₹6.97₹6.30
Dividend per share₹0.05₹0.05₹0.05₹0.05₹0.10₹0.10₹0.10₹0.10₹0.10₹0.10
Book value per share––₹9.68₹12.32₹17.89₹27.76₹35.88₹53.11₹59.97₹66.23
Dividend payout3.4%2.4%1.8%1.7%2.2%1.0%1.2%1.2%1.4%1.6%
Shareholder yield––––0.0%0.0%0.1%−3.5%0.0%0.0%
Market cap at the year end (₹ crore)5148395923728912,4141,8072,8333,3722,746

Ratios

Standalone, years to March.Gufic Biosciences PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue growth23.3%21.9%15.2%2.1%–59.8%−11.4%16.8%1.6%14.7%
Operating profit growth37.1%40.6%19.5%−2.3%–73.6%−7.6%8.3%−7.5%11.4%
Net profit growth55.8%40.4%35.9%5.0%–116.7%−16.8%8.1%−18.8%−9.7%
Earnings per share growth55.8%39.9%35.3%5.0%–116.9%−16.9%6.3%−20.3%−9.6%
––28.9%26.7%32.9%43.3%25.8%19.6%12.3%10.0%
–––−2.2 pts6.1 pts10.5 pts−17.5 pts−6.3 pts−7.2 pts−2.4 pts
From the net margin–––0.8 pts11.2 pts11.7 pts−2.7 pts−1.9 pts−3.9 pts−2.6 pts
From asset turnover–––−3.3 pts5.6 pts13.8 pts−16.8 pts−4.1 pts−1.9 pts0.3 pts
From borrowing–––0.3 pts−10.7 pts−15.0 pts2.0 pts−0.2 pts−1.4 pts−0.1 pts
Return on capital employed––23.9%17.8%30.0%39.8%17.0%15.2%12.5%11.4%
Cash conversion––––186.0%109.0%−33.4%−8.7%175.6%69.7%
Interest cover3.83.84.02.85.026.513.78.44.93.3
Debt to equity––1.271.120.300.200.900.600.520.58
Receivable days––1081039371109149140115
Inventory days––190225138102202188211281
Payable days––144223165125143156155173
Cash conversion cycle, days––1541046649167181197224
Working capital days––1311207553132171173189
Asset turnover––1.281.131.301.711.000.830.720.75
Assets per rupee of net worth––3.643.682.782.062.242.222.001.98
Sales per rupee of plant––14.5511.264.906.804.355.261.641.94
Capital spending to depreciation––––0.875.188.426.623.591.01
Plant being built, % of plant in use––40.0%96.3%13.5%35.7%106.7%200.3%4.4%4.6%
Revenue growth, operating profit growth, net profit growth and earnings per share growth are left blank for the year to Mar 2021: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
5.0%
Cash from operations against operating profit
29.3%
Measure10 years5 years3 years
Revenue growth, yearly rate–14.0%10.8%
Profit growth, yearly rate–7.4%−7.5%
Return on equity, average–22.2%14.0%
Return on capital employed, average–19.2%13.0%
Operating margin, average15.5%17.7%16.8%
Net margin, average8.1%10.0%8.6%
Asset turnover, average–1.000.77
Cash conversion cycle, days, average–164201
Interest cover, average7.611.45.5
Debt to equity, average–0.560.56

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations23715944
Cash from investing−492−205−31
Cash from financing3097832
Capital spending49621931
Dividends paid531
Shares bought back000
Shares issued for cash1001000
Borrowings raised425159100
Borrowings repaid968625

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––67336–
Altman Z-scorePublished threshold 1.81––4.172.745.779.074.15–––
Beneish M-scorePublished threshold −1.78––––−2.67−1.73−1.48−1.48––
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−6.3719.1242.9720.06––
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.730.270.38–
Receivables growth less revenue growthOur threshold 0 percentage points–––−4.37−13.35−38.0346.9443.78––
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––17.64−54.57−42.1878.20−8.22––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––4.88−2.83−0.200.233.46––
Assets under construction, years of additionsOur threshold 2 years of additions–––1.910.161.272.5526.93––
Effective tax ratePublished threshold 17.16 per cent36.6545.7638.4124.6423.3624.4425.31–––
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−1.62−0.64–––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
8 Sep 2026CRISIL Ratings LimitedBank FacilitiesCrisil A2+Review, Re-affirm40
8 Sep 2026CRISIL Ratings LimitedBank FacilitiesCrisil A-Review, Re-affirmStable45
10 Nov 2025ICRA LimitedNon Fund Based-Working capital facilities[ICRA]A2+Review, Re-affirm50
10 Nov 2025ICRA LimitedFund Based-Working capital facilities[ICRA]A-Review, Re-affirmStable100
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.